Popular on EntSun
- Disney Streamer Network Establishes Creator Code of Conduct - 386
- Commercial Manufacturing Validation Completed as November 10 FDA Milestone Approaches; Critical FDA Milestone Close: NRx Pharmaceuticals NAS DAQ: NRXP - 245
- Western Canadian Host James Cousineau Finishes 11th In Global "Top Host" Competition - 232
- Majo Aguilar inaugurates the Paseo de las Estrellas at Plaza Mexico with the unveiling of her Estrella Maya - 198
- Highsfield Showcases Earth Zoom Generator for Cinematic AI Videos - 190
- TÀBÍRA Studio Announces Permanent UK Entry and Upcoming London Showcase - 183
- Bacchus Wine & Spirits and Michelin Guide–Recommended Ethel's Fancy to Host Exclusive LOUIS XIII Limited Edition Diwali Decanter Celebration - 178
- The Return of Plaza México's 'Paseo de Las Estrellas' Honoring Recording Artist Majo Aguilar - 175
- OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki - 174
- Former Goddard Enterprises Managing Director Anthony Ali Joins STS Capital Partners as Managing Director and Partner - 173
Similar on EntSun
- What If the Greatest Gift This Holiday Season Came in a Dream of Your Loved One in Spirit?
- Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Minneapolis
- Record Q3 Revenue and Gross Profit Delivered: Revenue Surges 40%, Gross Margin Soars to 36% & Adjusted EBITDA Loss Narrows 64% for Cycurion, Inc $CYCU
- UK Financial Ltd Launches MayaSwap On MAYA CHAIN To Facilitate UKFLMS-For-Gold Swaps, Officially Transforming UKFLMS From Meme Into A Real-World Asset
- Entrepreneur Nouho M Kanneh Talks Family, Faith and a $37 Million Portfolio in New Interview
- Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
- Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
- Security Planning Tips For Your Holiday Event From Access Patrol Services
- Contracting Resources Group Receives 2026 HIRE Vets Platinum Medallion Award
- Kitchen Table Economics: An Invitation to Think Differently
New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX)
EntSun News/11106426
Roche Diagnostics $RHHBY Collaboration, Promising REQORSA® Biomarker Research, and Expanding Gene Therapy Programs Put Genprex $GNPX in the Spotlight
AUSTIN, Texas - EntSun -- Genprex, Inc. (N A S D A Q: GNPX) $GNPX is bringing renewed attention to its gene therapy platform with a new announcement today involving its sponsored research collaboration with Meharry Medical College. The research, centered on TUSC2—the tumor-suppressor gene used in Genprex's investigational REQORSA® gene therapy—will be presented at the Gerontological Society of America (GSA) 2026 Annual Scientific Meeting in November.
For investors following emerging biotechnology companies, this latest development adds another dimension to Genprex's scientific story. The company continues to investigate approaches designed to restore important biological functions, with programs targeting cancer and diabetes. Its expanding research into TUSC2 biology may provide valuable scientific insights beyond the gene's established role in oncology, while its clinical and development programs remain the central focus of its therapeutic ambitions.
Although Genprex remains a clinical-stage company facing the substantial uncertainties associated with drug development, today's announcement gives investors a fresh research milestone to watch as the company advances its broader platform.
Today's News: Genprex to Present New TUSC2 Research in November
Genprex announced on October 28 that research conducted through its sponsored collaboration with Meharry Medical College will be featured at the GSA 2026 Annual Scientific Meeting, scheduled for November 4–7 in National Harbor, Maryland. The presentation will examine TUSC2 gene therapy in relation to cellular resilience and biological processes associated with aging.
The scheduled presentation is titled "TUSC2 Gene Therapy in Humans Induces a Cellular-Resilience Program." It is listed for the conference's Late Breaking Poster Session I on November 4, from 6:00 to 7:15 p.m. Eastern Time. Genprex Chief Medical Officer Mark S. Berger, M.D., is identified as the presenter.
The announcement is notable because TUSC2 is already central to the company's oncology strategy. REQORSA, also known as quaratusugene ozeplasmid, is an investigational gene therapy designed to deliver the TUSC2 tumor-suppressor gene. The collaboration is examining the gene's wider biological activities, including mitochondrial metabolism, cellular stress responses and molecular processes associated with aging.
Genprex established the sponsored research collaboration with Meharry in 2024 and has continued to broaden its investigation into TUSC2 biology. The latest presentation offers another opportunity for the scientific community to examine findings generated through that work.
Importantly, the research should be viewed as an expansion of scientific understanding—not evidence that REQORSA treats aging or age-related diseases. Further investigation would be required to establish whether the findings support additional therapeutic applications.
For investors, the immediate takeaway is that Genprex continues to generate research milestones around a gene that underpins its lead oncology candidate, creating additional scientific visibility while its principal therapeutic programs progress.
More on EntSun News
October 21 Research Adds Another Layer to the TUSC2 Story
Today's announcement follows another important research update released October 21, when Genprex highlighted a peer-reviewed study published in Mechanisms of Ageing and Development. Researchers at Meharry Medical College investigated the role of TUSC2 in maintaining cellular function during brain aging.
The study examined an engineered mouse model in which TUSC2 was absent. Researchers associated TUSC2 loss with disruptions in mitochondrial function, protein quality control and pathways involved in communication between neurons. The effects differed between male and female mice, with more pronounced disruptions observed in males.
The researchers also examined existing human gene-expression datasets, finding that TUSC2 expression declined with age in 11 of 13 brain regions evaluated. Additional reductions were identified in Alzheimer's disease datasets, while comparisons revealed molecular similarities between the mouse findings and human brain-aging data.
Why does this matter to GNPX investors? TUSC2 is not simply a gene being studied in isolation; it is the foundation of the company's lead investigational oncology therapy. A deeper understanding of its biological functions could help researchers explore new scientific questions and refine their understanding of the company's platform.
However, the study was not a clinical trial of REQORSA for Alzheimer's disease, cognitive decline or aging. Any therapeutic implications outside oncology remain exploratory. The near-term investment case therefore continues to depend primarily on progress in Genprex's cancer and diabetes programs.
Roche Diagnostics Collaboration Targets More Personalized Lung Cancer Treatment
One of Genprex's most consequential recent strategic developments arrived on August 3, when the company announced a collaboration with Roche Diagnostics to conduct biomarker assay validation studies for non-small cell lung cancer (NSCLC).
The collaboration focuses on TROP2 and PTEN, two biomarkers that could help researchers identify patients more likely to respond to REQORSA. Earlier clinical findings presented at the 2026 American Society of Clinical Oncology meeting suggested that patients with higher TROP2 expression or lower PTEN expression experienced longer progression-free survival in the studied patient groups.
The Roche collaboration is designed to validate relevant biomarker testing methods, with Genprex anticipating completion around the end of 2026. Subject to the results, the company expects to evaluate incorporating the validated approach into its NSCLC clinical program.
This is an important development because identifying patients most likely to benefit from a treatment can be a valuable part of clinical development. Better patient selection could help researchers design more targeted studies and improve their understanding of treatment response.
For investors, the milestones to watch include validation results, potential incorporation of biomarker-based selection into clinical trials, and subsequent clinical data. These are prospective opportunities, not guarantees of improved outcomes or regulatory approval.
More on EntSun News
Diabetes Gene Therapy Advances Toward Manufacturing Scale-Up
Genprex is also developing a separate gene therapy program targeting diabetes, giving the company a second major therapeutic area beyond oncology.
On August 18, the company announced that it had selected a U.S.-based contract development and manufacturing organization to begin scaling up production of its adeno-associated virus (AAV)-based diabetes gene therapy. The manufacturing agreement is intended to support production under current Good Manufacturing Practice standards for investigational development and future clinical trials.
The candidate uses the Pdx1 and MafA genes, delivered to the pancreas using an AAV vector, with the goal of restoring insulin-producing beta-cell function.
Genprex has reported encouraging preclinical findings, including sustained blood-glucose improvements in Type 1 diabetes animal models and favorable measures involving insulin requirements, C-peptide and glucose tolerance in non-human primate studies. Related approaches have also shown encouraging findings in Type 2 diabetes models. These results remain preclinical and do not establish effectiveness in humans.
The manufacturing step is nevertheless meaningful: developing a potential therapy requires not only a scientific rationale but also a reproducible production process capable of supporting formal studies. Genprex's work on manufacturing and delivery approaches could help prepare the program for subsequent development milestones.
Additional Developments Investors Should Watch
Several other developments round out Genprex's current investment narrative:
Genprex also reported regaining Nasdaq's minimum-bid-price compliance on August 5. The associated panel requirements included maintaining a closing bid price of at least $1.00 through December 7, 2026, making continued listing compliance another important item to monitor.
$GNPX Outlook: Scientific Progress Meets Important Upcoming Milestones
Genprex enters the final months of 2026 with several developments that warrant attention: fresh TUSC2 research, a scheduled scientific presentation, biomarker validation work with Roche Diagnostics and manufacturing preparations for its diabetes program.
The company's opportunity rests on whether its scientific platform can translate into reproducible clinical benefits and, ultimately, viable treatments. The next meaningful checkpoints include the GSA presentation, further updates on the REQORSA clinical program, Roche-related validation progress and additional diabetes development announcements.
For more information on $GNPX visit: www.genprex.com and https://compasslivemedia.com/gnpx/
Media Contact:
Company Name: Genprex, Inc.
Contact: Kalyn Dabbs
Email: media@genprex.com
Phone: (877) 774-GNPX (4679)
Country: United States
Website: www.genprex.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
For investors following emerging biotechnology companies, this latest development adds another dimension to Genprex's scientific story. The company continues to investigate approaches designed to restore important biological functions, with programs targeting cancer and diabetes. Its expanding research into TUSC2 biology may provide valuable scientific insights beyond the gene's established role in oncology, while its clinical and development programs remain the central focus of its therapeutic ambitions.
Although Genprex remains a clinical-stage company facing the substantial uncertainties associated with drug development, today's announcement gives investors a fresh research milestone to watch as the company advances its broader platform.
Today's News: Genprex to Present New TUSC2 Research in November
Genprex announced on October 28 that research conducted through its sponsored collaboration with Meharry Medical College will be featured at the GSA 2026 Annual Scientific Meeting, scheduled for November 4–7 in National Harbor, Maryland. The presentation will examine TUSC2 gene therapy in relation to cellular resilience and biological processes associated with aging.
The scheduled presentation is titled "TUSC2 Gene Therapy in Humans Induces a Cellular-Resilience Program." It is listed for the conference's Late Breaking Poster Session I on November 4, from 6:00 to 7:15 p.m. Eastern Time. Genprex Chief Medical Officer Mark S. Berger, M.D., is identified as the presenter.
The announcement is notable because TUSC2 is already central to the company's oncology strategy. REQORSA, also known as quaratusugene ozeplasmid, is an investigational gene therapy designed to deliver the TUSC2 tumor-suppressor gene. The collaboration is examining the gene's wider biological activities, including mitochondrial metabolism, cellular stress responses and molecular processes associated with aging.
Genprex established the sponsored research collaboration with Meharry in 2024 and has continued to broaden its investigation into TUSC2 biology. The latest presentation offers another opportunity for the scientific community to examine findings generated through that work.
Importantly, the research should be viewed as an expansion of scientific understanding—not evidence that REQORSA treats aging or age-related diseases. Further investigation would be required to establish whether the findings support additional therapeutic applications.
For investors, the immediate takeaway is that Genprex continues to generate research milestones around a gene that underpins its lead oncology candidate, creating additional scientific visibility while its principal therapeutic programs progress.
More on EntSun News
- Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Minneapolis
- Holiday Events coming to the Weinberg Center and New Spire Arts this season
- LGF Lab Gas Flow Launches Fully Automatic Laboratory Gas Changeover Manifold System with Ultra High Purity Gas Regulator Valve
- From Startup to Successful Fashion Brand: How Laurent Gabay & Fashion Sourcing Help New Clothing Br
- Record Q3 Revenue and Gross Profit Delivered: Revenue Surges 40%, Gross Margin Soars to 36% & Adjusted EBITDA Loss Narrows 64% for Cycurion, Inc $CYCU
October 21 Research Adds Another Layer to the TUSC2 Story
Today's announcement follows another important research update released October 21, when Genprex highlighted a peer-reviewed study published in Mechanisms of Ageing and Development. Researchers at Meharry Medical College investigated the role of TUSC2 in maintaining cellular function during brain aging.
The study examined an engineered mouse model in which TUSC2 was absent. Researchers associated TUSC2 loss with disruptions in mitochondrial function, protein quality control and pathways involved in communication between neurons. The effects differed between male and female mice, with more pronounced disruptions observed in males.
The researchers also examined existing human gene-expression datasets, finding that TUSC2 expression declined with age in 11 of 13 brain regions evaluated. Additional reductions were identified in Alzheimer's disease datasets, while comparisons revealed molecular similarities between the mouse findings and human brain-aging data.
Why does this matter to GNPX investors? TUSC2 is not simply a gene being studied in isolation; it is the foundation of the company's lead investigational oncology therapy. A deeper understanding of its biological functions could help researchers explore new scientific questions and refine their understanding of the company's platform.
However, the study was not a clinical trial of REQORSA for Alzheimer's disease, cognitive decline or aging. Any therapeutic implications outside oncology remain exploratory. The near-term investment case therefore continues to depend primarily on progress in Genprex's cancer and diabetes programs.
Roche Diagnostics Collaboration Targets More Personalized Lung Cancer Treatment
One of Genprex's most consequential recent strategic developments arrived on August 3, when the company announced a collaboration with Roche Diagnostics to conduct biomarker assay validation studies for non-small cell lung cancer (NSCLC).
The collaboration focuses on TROP2 and PTEN, two biomarkers that could help researchers identify patients more likely to respond to REQORSA. Earlier clinical findings presented at the 2026 American Society of Clinical Oncology meeting suggested that patients with higher TROP2 expression or lower PTEN expression experienced longer progression-free survival in the studied patient groups.
The Roche collaboration is designed to validate relevant biomarker testing methods, with Genprex anticipating completion around the end of 2026. Subject to the results, the company expects to evaluate incorporating the validated approach into its NSCLC clinical program.
This is an important development because identifying patients most likely to benefit from a treatment can be a valuable part of clinical development. Better patient selection could help researchers design more targeted studies and improve their understanding of treatment response.
For investors, the milestones to watch include validation results, potential incorporation of biomarker-based selection into clinical trials, and subsequent clinical data. These are prospective opportunities, not guarantees of improved outcomes or regulatory approval.
More on EntSun News
- Inaugural 12 Trees of Christmas gala raises $525,000 for DMG research and family support
- BitTitan Expands MigrationWiz with SharePoint Sites Migration and Simplified Collaboration Licensing
- How Murder Mystery Games Work: The Technology Behind a Fully Automated Format
- BGE DD and Producer 9-0 Sets April 1, 2027 Release for The Royal Chamber
- Producer 9-0 Announces The Grand Salon and Salutes His Baroque Collaborators
Diabetes Gene Therapy Advances Toward Manufacturing Scale-Up
Genprex is also developing a separate gene therapy program targeting diabetes, giving the company a second major therapeutic area beyond oncology.
On August 18, the company announced that it had selected a U.S.-based contract development and manufacturing organization to begin scaling up production of its adeno-associated virus (AAV)-based diabetes gene therapy. The manufacturing agreement is intended to support production under current Good Manufacturing Practice standards for investigational development and future clinical trials.
The candidate uses the Pdx1 and MafA genes, delivered to the pancreas using an AAV vector, with the goal of restoring insulin-producing beta-cell function.
Genprex has reported encouraging preclinical findings, including sustained blood-glucose improvements in Type 1 diabetes animal models and favorable measures involving insulin requirements, C-peptide and glucose tolerance in non-human primate studies. Related approaches have also shown encouraging findings in Type 2 diabetes models. These results remain preclinical and do not establish effectiveness in humans.
The manufacturing step is nevertheless meaningful: developing a potential therapy requires not only a scientific rationale but also a reproducible production process capable of supporting formal studies. Genprex's work on manufacturing and delivery approaches could help prepare the program for subsequent development milestones.
Additional Developments Investors Should Watch
Several other developments round out Genprex's current investment narrative:
- Clinical biomarker research: Findings presented at ASCO in May 2026 added to the company's investigation of biomarkers associated with REQORSA treatment response.
- Intellectual property: On June 22, Genprex announced a notice of allowance from the Canadian Intellectual Property Office for a patent claim involving REQORSA combined with PD-1 or PD-L1 antibodies for cancer treatment.
- Upcoming scientific visibility: The November 4–7 GSA meeting provides the next specifically announced research presentation highlighted in the October 28 release.
Genprex also reported regaining Nasdaq's minimum-bid-price compliance on August 5. The associated panel requirements included maintaining a closing bid price of at least $1.00 through December 7, 2026, making continued listing compliance another important item to monitor.
$GNPX Outlook: Scientific Progress Meets Important Upcoming Milestones
Genprex enters the final months of 2026 with several developments that warrant attention: fresh TUSC2 research, a scheduled scientific presentation, biomarker validation work with Roche Diagnostics and manufacturing preparations for its diabetes program.
The company's opportunity rests on whether its scientific platform can translate into reproducible clinical benefits and, ultimately, viable treatments. The next meaningful checkpoints include the GSA presentation, further updates on the REQORSA clinical program, Roche-related validation progress and additional diabetes development announcements.
For more information on $GNPX visit: www.genprex.com and https://compasslivemedia.com/gnpx/
Media Contact:
Company Name: Genprex, Inc.
Contact: Kalyn Dabbs
Email: media@genprex.com
Phone: (877) 774-GNPX (4679)
Country: United States
Website: www.genprex.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Source: CorporateAds
0 Comments
Latest on EntSun News
- Producer 9-0 Credits Southern Miss and Ole Miss as Baroque Project Takes Shape
- Resident Evil's Wesker Is Now Beavis's "Bold New Voice" on Mike Judge's Beavis & Butt-Head
- Resident Evil's Wesker, D.C. Douglas, Plays the Villain in Texas Horror-Noir WHAT DID YOU DO?
- Hollywood Glam Night, December 30th, Marilyn Monroe Foundation & Anastasia Magazine
- Canadian Streamer CGP Spotlight Marks One Year With 1,000-Title Challenge
- Nine Platinum Honors Lead Scientology Media Productions' 12 Wins at 2026 MarCom Awards
- Entrepreneur Nouho M Kanneh Talks Family, Faith and a $37 Million Portfolio in New Interview
- The Creative Vision Behind Hollywood Music in Media Award-Nominated Mark Isham: The Voice Within
- Emerald Williams Selected to Super Lawyers Rising Stars 2022-2026
- El Show de Bernie: NJ Studio Launches Latino Animated Late-Night Talk Show Hosted by a Mexican Bear
- 98.FM Gospel Radio Realigns Airwaves: Prioritizing Scripture and New Artists Over Secular Metrics
- Entertainment Vet Latrina Blackberry Brings Upscale 40+ Experience "The Congo Den" to Spring, Texas
- Music For Good: Brooklyn's Legendary Gleason's Gym Transforms Into A Live Music Venue For One Night
- Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
- The Dining Room Sees Everything
- Orlando Real Estate Broker Bent Danholm Wins 2026 Goody Business Book Award for The Architecture of Demand
- Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
- Independent Producer/Writer Karen Morris Announces The Swingin' Angle
- The King Returns: Satirical December 2026 Rematch Sees Challenger Delayed by a Christmas Light Installation
- Last Night of the Proms 2027 Tickets and Private Boxes on Sale at the Royal Albert Hall


